Ascend Recalls Tizanidine Tablets for Failed Dissolution Specifications
Ascend Laboratories LLC is recalling 1,200 bottles of Tizanidine 4mg tablets distributed in Michigan due to failed dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which is a reasonable probability of temporary or medically reversible adverse health consequences. The hazard is a quality control failure (dissolution) without reported injuries or illnesses, fitting the Moderate category for low-risk contamination or voluntary precautionary recalls.
Plain-English summary
Ascend Laboratories LLC is recalling 1,200 bottles of Tizanidine Tablets, USP 4mg, NDC 67877-614-15. The affected product is identified by Lot #19143017 and has an expiration date of 05/31/2021. The tablets were manufactured by Alkem Laboratories Ltd in India and distributed by Ascend Laboratories LLC in Parsippany, NJ.
The recall was initiated because the product failed dissolution specifications, resulting in out-of-specification (low) results. This means the tablets may not dissolve at the rate required by the United States Pharmacopeia, potentially affecting the drug's performance.
The affected product was distributed in Michigan. Consumers who have this specific lot of Tizanidine should stop using it and contact their healthcare provider or pharmacist for guidance on obtaining a replacement or alternative medication.
The recalled product
- Product
- TIZANIDINE (TIZANIDINE)
- Brand
- TIZANIDINE
- Manufacturer
- Ascend Laboratories LLC
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 1,200
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #19143017
- Exp. 05/31/2021
Distribution
Distributed in 1 state:
Related recalls
Same brand · TIZANIDINE
- HighTizanidine 4mg Tablets Recalled for Contamination with 2mg Tablets
FDA (Drugs) · 2024-01-17
- HighTizanidine Tablets Recalled Nationwide for Failed Dissolution Specification
FDA (Drugs) · 2023-07-26
- ModeratePrescription Drug Tizanidine Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2023-07-12
- ModerateTizanidine tablets recalled nationwide for failed stability specifications
FDA (Drugs) · 2023-07-12
- ModerateTizanidine Tablets Recalled for Failed Specifications Due to Shaved Tablets
FDA (Drugs) · 2021-08-25
Same manufacturer · Ascend Laboratories LLC
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Over Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateFDA Recalls Amlodipine and Olmesartan Tablets Over Failed Dissolution Test
FDA (Drugs) · 2026-07-29
- ModerateDabigatran Etexilate Capsules Recalled Over Impurity Test Failure
FDA (Drugs) · 2026-07-29
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22